Compare Nokia Corp (NOK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Nokia Corp trades at $10.19 (market cap $51.87B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.6× Nokia Corp's market cap, and Nokia Corp pays a 1.79% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NOK | VRTX | |
|---|---|---|
Market Cap | $51.87B | $132.79B |
Sector | Technology | Health |
52-Week High | $16.83 | $529.65 |
52-Week Low | $4.13 | $376.62 |
Enterprise Value | $49.82B | $126.92B |
Dividend Yield | 1.79% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
